Company Profile for Acucela Inc.

--()--Acucela Inc. is a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, which could impact millions of individuals worldwide. Acucela currently has the following co-development agreements with Otsuka Pharmaceutical Co., Ltd.: emixustat hydrochloride, its lead investigational drug candidate for geographic atrophy associated with dry age-related macular degeneration based on Acucela’s proprietary visual cycle modulation technology; and OPA-6566, an investigational compound originating from Otsuka for the treatment of ocular hypertension and glaucoma.

   

Company:

Acucela Inc.
 

Headquarters Address:

1301 2nd Ave #4200
Seattle, WA 98101
 

Main Telephone:

(206) 805-8300
 

Website:

www.acucela.com

 

Ticker:

4589(TOKYO)
 

Type of Organization:

Public
IRPR
 

Industry:

Biotechnology
 

Key Executives:

CEO: Ryo Kubota

 

Corporate Communications

Contact:

Corporate Communications

Phone:

206-805-8300

Email:

pr@acucela.com